Consider shorting the quantum computing sector, with IonQ (INQ) being a "favorite short" and BTQ being a "great short" with a price target of $1. For a high-risk speculative play, Abivax (ABVX) is viewed as a potential merger target with a speculative buyout price of $150 to $200. The analyst suggests buying Bitcoin (BTC) now, with a potential future price target of $88,000 to $90,000. A high-conviction long idea is Taiwan Semiconductor Manufacturing (TSM), which the analyst loves. While long-term bullish on NVIDIA (NVDA), the current market reaction suggests waiting for a better entry point.

NVIDIA (NVDA)

• The host notes that NVIDIA reported "spectacular" earnings with a "huge beat" and "huge guidance raise," yet the stock's reaction was "tepid."
• He mentions the market seems to be in a "sell the news" mode, where good news was already expected and priced in.
• The market's main question is about the sustainability of demand. It is looking for validation from AI application companies like OpenAI and Anthropic (which are private) to prove that the massive GPU purchases are rational and will lead to real revenue.
• He believes NVIDIA is a "great company" and a "good long" but feels he doesn't "need to own Nvidia this moment."
• He mentions he might buy NVIDIA at some point and that it could become the "world's first 10 trillion dollar company."

Takeaways

• Long-term Bullish, Short-term Cautious: While the company's fundamentals are incredibly strong, the stock's inability to rally on great news is a short-term bearish signal.
• Watch the AI Ecosystem: The future of NVIDIA's stock price may depend on the success and reported revenues of companies using its chips. Since many are private, this creates uncertainty.
• Potential Buying Opportunity: The host suggests he is waiting for a better entry point to buy the stock, possibly after the current market skepticism subsides.

Quantum Computing Sector (INQ, QBTS, RGTI, BTQ)

• The host is extremely bearish on the quantum computing sector, referring to it as a "bubble" that is "finally popping." He frequently mentions the "quantum meltdown."
• He is actively shorting several stocks in this space and views their weakness as a very negative sign for the sector.
• IonQ (INQ): This is his "favorite short." He holds a large number of put options, betting on the price to fall. He believes the stock's decline is "just starting."
• BTQ: He calls this one of his "bigger shorts" and a "great short," stating he believes it is going to $1.
• D-Wave (QBTS) & Rigetti (RGTI): He mentions he might short these stocks as well, lumping them into the overall negative trend in quantum computing.

Takeaways

• Strong Bearish Sentiment: The host believes the entire quantum computing sector is overvalued and is in the process of a major correction.
• Active Short Positions: He is not just talking about the sector's weakness; he is actively betting against it with significant short positions, particularly in INQ and BTQ.
• Risk Factor: The weakness in these stocks, even when the broader market is up, is seen as a major red flag indicating a lack of investor confidence.

Agios Pharmaceuticals (AGIO)

• The host had a successful short-term trade on AGIO, buying the stock at $22 and selling around $25 after a "beautiful rally."
• He notes the company has strong fundamentals, calling it "pretty undervalued" due to:
  • An approved drug that is selling.
  • A "mountain of cash."
  • Potential for its drug to be used for thalassemia, a different condition.
• Despite the positive outlook, he sold his position because the stock went up "a good amount very quickly."

Takeaways

• Take Profits on Quick Wins: This trade serves as an example of a strategy to lock in profits after a rapid price increase, even if you are bullish on the company's long-term prospects.
• Fundamentally Undervalued: The host believes AGIO has a solid foundation, making it a company to watch. The combination of an approved product, strong cash position, and pipeline potential is a positive sign.

Olema Oncology (OLMA)

• The host is short OLMA, but acknowledges it has been a painful trade due to strong buying pressure.
• He is fundamentally skeptical of the company's long-term value, noting it was a "single-digit stock pretty recently."
• He questions the excitement around the company's drug, suggesting it would be the "fifth or sixth" to market in its class, which he views as an unattractive competitive position.
• Despite the stock's rally against him, he believes it could fade back to the $22 level.

Takeaways

• Bearish on Fundamentals: The host's short thesis is based on the belief that the company's competitive position is weak and the recent stock rally is overdone.
• High Short-Term Risk: He acknowledges that a "big drug fund wants in," creating significant upward momentum that makes shorting the stock risky in the near term.

Abivax (ABVX)

• The host describes ABVX as a former "safest long," but immediately clarifies that it is a "dangerous" high-risk biotech play.
• He speculates that the company is a likely M&A (merger and acquisition) target and could announce a deal at the upcoming JP Morgan conference.
• He provides a speculative buyout price target of $150 or $200 per share.

Takeaways

• Speculative M&A Play: The investment thesis here is based on the potential for the company to be acquired, which could lead to a significant premium on its stock price.
• High Risk, High Reward: This is a high-risk investment. While a buyout could lead to a large gain, there is no guarantee it will happen.

Palantir (PLTR)

• The host views Palantir as a direct competitor to OpenAI, but with a different business model. He states Palantir's approach is "we do it for you," whereas OpenAI offers a "do it yourself" tool.
• He mentions that he is considering buying PLTR at some point, along with NVIDIA.
• He also suggests that buying Palantir could serve as a "good hedge."

Takeaways

• Bullish on AI Position: Palantir is seen as a key player in the enterprise AI space with a distinct service-oriented approach.
• Potential Long-Term Buy: The host has put PLTR on his watchlist as a stock to potentially buy for long-term AI exposure.

Other Mentions

• Exact Sciences (EXAS): The company was acquired by Abbott (ABT), causing the stock to jump 18%. This is a past event, but a positive outcome for former shareholders.
• Abbott (ABT): The stock was down after announcing its acquisition of Exact Sciences, indicating a negative market reaction to the deal.
• BioHaven (BHVN): Described as a "high-quality company with smart management and good assets." A generally positive but non-specific mention.
• Bitcoin (BTC): The host makes a brief, bullish comment to "download some Bitcoin now" and mentions speculative future price points of $88,000 - $90,000.
• TSM (Taiwan Semiconductor Manufacturing): When asked for a favorite long idea, TSM is mentioned, and the host responds, "Oh, I love it," indicating strong bullish sentiment.